Biotechnology Analysts Minter & Lugo, along with Felix Ratjen, MD, PhD, discuss current clinical management and next-generation treatment options for patients with cystic fibrosis (CF), as well as the recently released pivotal Phase III data from Vertex’s SKYLINE trials on an Analyst/Industry conference call to be held on March 15 at 11:30 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- William Blair biotech analysts to hold an analyst/industry conference call
- Vertex Pharmaceuticals participates in a conference call with JPMorgan
- Vertex Pharmaceuticals downgraded to Buy from Conviction Buy at Goldman Sachs
- Vertex Pharmaceuticals CSO Altshuler sells 3,002 common shares
- Vertex Pharmaceuticals reports CHMP opinion for label extension of Kalydeco
